Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Association between Obesity and Efficacy of Psoriasis Therapies: An Expert Consensus Panel.
Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van Voorhees A, Lebwohl M. Burshtein J, et al. Among authors: merola j. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03390-5. doi: 10.1016/j.jaad.2024.12.016. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709077
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.
Zhang AJ, Ball G, Zundell MP, Agüero R, Yee D, Shields A, Asare C, Navrazhina K, Liu W, Foolad N, Kwock J, Tejwani P, Hamade H, Jaleel T, Butler D, Silverberg N, Nattkemper L, Siegel DM, Tan J, Kim BS, Larocca C, Shinohara MM, Ehlert A, Latella J, Guttman-Yassky E, Krueger JG, Strand V, Armstrong AW, Merola JF, Perez-Chada L, Gottlieb AB. Zhang AJ, et al. Among authors: merola jf. J Drugs Dermatol. 2024 Dec 1;23(12):1114-1120. doi: 10.36849/jdd.8363. J Drugs Dermatol. 2024. PMID: 39630678
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Merola JF, et al. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. Dermatol Ther (Heidelb). 2024. PMID: 39578348 Free PMC article.
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.
Mease PJ, Baraliakos X, Chandran V, Soriano ER, Nash P, Deodhar A, Rampakakis E, Shiff NJ, Chakravarty SD, Shawi M, Merola JF, McInnes IB. Mease PJ, et al. Among authors: merola jf. ACR Open Rheumatol. 2024 Dec;6(12):880-890. doi: 10.1002/acr2.11732. Epub 2024 Oct 4. ACR Open Rheumatol. 2024. PMID: 39365294 Free PMC article.
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System.
Schneeweiss MC, Glynn RJ, Wyss R, Anand P, Jin Y, Landon J, Mostaghimi A, Merola JF, Silverberg JI, Rosmarin DM, Sidbury R, Schneeweiss S. Schneeweiss MC, et al. Among authors: merola jf. J Invest Dermatol. 2024 Oct 1:S0022-202X(24)02169-9. doi: 10.1016/j.jid.2024.08.034. Online ahead of print. J Invest Dermatol. 2024. PMID: 39362623
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
Husni ME, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Husni ME, et al. Among authors: merola jf. RMD Open. 2024 Sep 23;10(3):e004464. doi: 10.1136/rmdopen-2024-004464. RMD Open. 2024. PMID: 39313302 Free PMC article. Clinical Trial.
464 results